Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Low Dose REN001
OnKure Therapeutics
Fatty Acid Oxidation Disorders
1 trial -
Low dose ET019002- T Cells
The First People's Hospital of Lianyungang
B-Cell Malignancies
1 trial -
Low-dose RSV mRNA vaccine
Sinovac Research and Development Co.,
RSV
1 trial -
M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors
The George Institute
Patients with pretreated, metastatic or locally advanced cancer for the dose escalation part and dose expansion cohorts in patients with advanced triple-negative breast cancers and advanced cancers with ATM mutation.
1 trial -
MIRROR; Multispectral and bimodal fluorescent guided surgery (FGS) of high-grade glioma for refining margin assessment: A phase 1 dose finding study using Cetuximab-IRDye800CW- combined with 5-ALA
Disc Medicine
Glioblastoma
1 trial -
MK-4646 Single Ascending Dose Study and DDI in Healthy Participants
Merck Sharp and Dohme
HIV infection
1 trial -
MK-7480 Multiple Ascending Dose Study in Healthy Participants
Merck Sharp and Dohme
Non-alcoholic steatohepatitis
1 trial -
MOR106 single ascending doses, intravenous
Lakefront Biotherapeutics NV
Healthy
1 trial -
MT-601 dose 200 million cells
Marker Therapeutics
Pancreas Cancer
1 trial -
Multiple Ascending Dose Study of LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis
Eli Lilly Co.
Sporadic Amyotrophic Lateral Sclerosis
1 trial -
Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus
Bristol-Myers Squibb Australia Pty Ltd
Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus, Systemic Lupus Erythematosus
1 trial -
Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives
Hoffmann-La Roche
Healthy Overweight or Obese
1 trial -
Multiple-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Participants.
Laboratorios Tillomed Spain S.L.U
No medical condition.
1 trial -
Multiple-Dose Bioequivalence of Mirabegron 50 mg Prolonged-Release Tablets in Healthy Participants Under Fasting Conditions.
Laboratorios Tillomed Spain S.L.U
No medical condition.
1 trial -
Multiple-Dose Study in Healthy Participants Under Fasting Conditions to Evaluate the Bioequivalence of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide SR 1.5 mg and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg.
The George Institute
No medical condition.
1 trial -
Multiple-Dose Study on the Bioequivalence of One Tablet of Gliclazide MR 120 mg (S005190) and Two Tablets of Gliclazide MR 60 mg (Diaprel® MR) in Healthy Participants under Fed Conditions.
The George Institute
No medical condicion.
1 trial -
Multiple-dose, open-label, laboratory blinded, randomized, 2-period, 2-sequence, crossover, steady-state bioequivalence study comparing the Test Product Naproxen sodium 660 mg modified release tablets with the Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.
Laboratorios Tillomed Spain S.L.U
No medical condition
1 trial -
Naloxone
BRIGHT MINDS BIOSCIENCES INC.
Drug Overdose
1 trial -
Nezulcitinib (TD-0903) Dose A
Theravance Biopharma Ireland Umited
Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
1 trial -
ORIC-114 Dose 1 + amivantamab
Topiloric/Uriadec
Solid Tumors
1 trial -
Odronextamab multiple dose levels
Regeneron UK Limited
Non-Hodgkin Lymphoma
1 trial -
One dose of investigational vaccine
Sinovac Research and Development Co.,
Hepatitis B
1 trial -
Open label, single-center, two-part pharmacokinetic study: Part I: Relative bioavailability study to compare the pharmacokinetics of BP1.4979 after administration of single oral doses of BP1.4979 as sustained release formulation and actual immediate release formulation, under fasting and fed conditions, in healthy subjects. Part II: Pharmacokinetics of BP1.4979 after a 14-day dosing period with b.i.d. administration of BP1.4979 as sustained release formulation in healthy subjects.
Bioprojet Pharma
Binge eating disorder
1 trial -
Open-label, non-randomised, single-dose, one sequence, two-period, cross-over study to investigate the effect of inhibition of P-glycoprotein and breast cancer resistance protein transporters by cyclosporine on the pharmacokinetics of CHF6001 in healthy volunteers.
Chiesi Farmaceutici S.p.A
Chronic obstructive pulmonary disease
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources